Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + amlodipine + atorvastatin (Shinpoong Pharma)
- Development stage
- Phase 1
- Lead developer
- Shinpoong Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SPC5003 is a fixed-dose triple combination therapy developed by Shin Poong Pharmaceutical for the treatment of patients with essential hypertension and comorbid dyslipidemia. The product combines three well-established pharmacological agents: candesartan cilexetil, an angiotensin II receptor blocker (ARB); amlodipine besylate, a dihydropyridine calcium channel blocker (CCB); and atorvastatin calcium, an HMG-CoA reductase inhibitor (statin). By integrating two antihypertensive mechanisms with a lipid-lowering agent into a single daily tablet, SPC5003 aims to simplify complex treatment regimens, enhance patient adherence, and provide comprehensive cardiovascular risk management. The drug is currently in Phase 3 clinical development, with studies evaluating its efficacy and safety compared to dual-combination and monotherapy components.
- Other names
- candesartan cilexetil + amlodipine besylate + atorvastatin calcium
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on candesartan + amlodipine + atorvastatin (Shinpoong Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + amlodipine + atorvastatin (Shinpoong Pharma).